Based on 1 Wall Street analysts offering 12 month price targets for Livzon Pharmaceutical Group in the last 3 months. The average price target is $2.96 with a high forecast of $2.96 and a low forecast of $2.96. The average price target represents a -9.76% change from the last price of $3.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","1.75":"$1.75","2.5":"$2.5","3.25":"$3.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.95529921,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.95529921,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,1.75,2.5,3.25,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.41,3.3750230161538464,3.3400460323076926,3.305069048461539,3.2700920646153846,3.235115080769231,3.200138096923077,3.1651611130769233,3.1301841292307695,3.0952071453846157,3.0602301615384615,3.0252531776923077,2.990276193846154,{"y":2.95529921,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.41,3.3753846153846156,3.3407692307692307,3.306153846153846,3.2715384615384617,3.236923076923077,3.2023076923076923,3.167692307692308,3.1330769230769233,3.0984615384615384,3.063846153846154,3.029230769230769,2.9946153846153845,{"y":2.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.41,3.3750230161538464,3.3400460323076926,3.305069048461539,3.2700920646153846,3.235115080769231,3.200138096923077,3.1651611130769233,3.1301841292307695,3.0952071453846157,3.0602301615384615,3.0252531776923077,2.990276193846154,{"y":2.95529921,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.43,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.42,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.19,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.27,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.92,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.07,"date":1700784000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1701388800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1728604800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$2.96

Average Price Target$2.96

Lowest Price Target$2.96

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

xxxxxxxxxxxxxxxxxx

Morgan Stanley

xxxxxxxxxxxxx

Reiterated

10/25/24

xxxxxxxxxxxxx

Linda Shu

HSBC

$3.6→$4.5

Buy

37.11%

Upside

Upgraded

01/17/24

HSBC Upgrades Livzon Pharmaceutical Group Inc. (1513:HK) (LVZPF) to BuyHSBC analyst Linda Shu upgraded Livzon Pharmaceutical Group Inc. (1513:HK) (OTC: LVZPF) from Hold to Buy with a price target of HK$35.00 (from HK$28.00).

Best Analysts Covering Livzon Pharmaceutical Group

Which Analyst Should I Follow If I Want to Buy LVZPF and Sell After:

1 Month

xxx

Success Rate

1/4 ratings generated profit

Average Return

+1.85%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 25.00% of your transactions generating a profit, with an average return of +1.85% per trade.

3 Months

xxx

Success Rate

3/4 ratings generated profit

Average Return

+5.70%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +5.70% per trade.

1 Year

Sean Wu CFAMorgan Stanley

Success Rate

3/4 ratings generated profit

Average Return

+5.42%

reiterated a sell rating last month

Copying Sean Wu CFA's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +5.42% per trade.

2 Years

xxx

Success Rate

3/4 ratings generated profit

Average Return

+6.75%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +6.75% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LVZPF Analyst Recommendation Trends

Rating

Sep 22

Sep 23

Oct 23

Jan 24

Oct 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LVZPF has received 2 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. LVZPF average Analyst price target in the past 3 months is $2.96.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

LVZPF Financial Forecast

LVZPF Earnings Forecast

Next quarter’s earnings estimate for LVZPF is $0.06 with a range of $0.05 to $0.06. The previous quarter’s EPS was $0.07. LVZPF beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.91% of the time in the same period. In the last calendar year LVZPF has Underperformed its overall industry.

LVZPF Sales Forecast

Next quarter’s sales forecast for LVZPF is $383.18M with a range of $383.18M to $383.18M. The previous quarter’s sales results were $386.59M. LVZPF beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.68% of the time in the same period. In the last calendar year LVZPF has Underperformed its overall industry.

LVZPF Stock Forecast FAQ

What is LVZPF’s average 12-month price target, according to analysts?

Based on analyst ratings, Livzon Pharmaceutical Group Inc Class H’s 12-month average price target is $2.96.

What is LVZPF’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for LVZPF, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LVZPF a Buy, Sell or Hold?

Livzon Pharmaceutical Group Inc Class H has a consensus rating of Moderate Sell which is based on 0 buy ratings, 0 hold ratings and 1 sell ratings.

What is Livzon Pharmaceutical Group Inc Class H’s price target?

The average price target for Livzon Pharmaceutical Group Inc Class H is $2.96. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $2.96 ,the lowest forecast is $2.96. The average price target represents -9.76% Decrease from the current price of $3.28.

What do analysts say about Livzon Pharmaceutical Group Inc Class H?

Livzon Pharmaceutical Group Inc Class H’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of LVZPF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Livzon Pharmaceutical Group (LVZPF) Stock Forecast & Price Target

LVZPF Analyst Ratings

LVZPF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Livzon Pharmaceutical Group

LVZPF Analyst Recommendation Trends

LVZPF Financial Forecast

LVZPF Earnings Forecast

LVZPF Sales Forecast

LVZPF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts